Literature DB >> 31055966

Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample.

Kenneth S Kendler1, Henrik Ohlsson1, Jan Sundquist1, Kristina Sundquist1.   

Abstract

OBJECTIVE: The objective of this study was to clarify the etiology of substance-induced psychotic disorder and its progression to schizophrenia in a Swedish national sample.
METHODS: Individuals with a registration of substance-induced psychotic disorder between 1997 and 2015 in national medical registries (N=7,606) were followed up for a mean of 84 months. Data from medical, criminal, and pharmacy registries on first-degree through third-degree relatives were used to calculate familial risk scores for nonaffective psychosis, drug abuse, and alcohol use disorder.
RESULTS: Individuals with substance-induced psychotic disorder had large elevations in standardized familial risk scores for drug abuse (+1.09, 95% CI=1.02, 1.15) and alcohol use disorder (+0.98, 95% CI=0.93, 1.03) and modest elevations for nonaffective psychosis (+0.35, 95% CI=0.30, 0.41). The cumulative risk for progression to schizophrenia was 11.3%; it was lowest for alcohol-induced and highest for cannabis-induced psychotic disorder, and it was predicted by early age at diagnosis of substance-induced psychotic disorder, male sex, and further registrations for episodes of drug abuse, alcohol use disorder, and substance-induced psychotic disorder. A risk prediction model found that 47% of individuals who converted to schizophrenia were in the upper 20% of risk. Familial risk scores for drug abuse and alcohol use disorder did not significantly discriminate those who converted to schizophrenia from those who did not, while familial risk score for nonaffective psychosis did (0.67, 95% CI=0.40, 0.95, versus 0.33, 95% CI=0.28, 0.39). Familial risk scores for nonaffective psychosis were indistinguishable between individuals with schizophrenia with and without prior substance-induced psychosis. Assignment of early retirement by the Swedish Social Insurance Agency strongly discriminated between individuals with substance-induced psychotic disorder with and without later schizophrenia.
CONCLUSIONS: Substance-induced psychotic disorder appears to result from substantial drug exposure in individuals at high familial risk for substance abuse and moderately elevated familial risk for psychosis. Familial risk for psychosis, but not substance abuse, predicts progression from substance-induced psychosis to schizophrenia. Schizophrenia following substance-induced psychosis is likely a drug-precipitated disorder in highly vulnerable individuals, not a syndrome predominantly caused by drug exposure.

Entities:  

Keywords:  Psychoses-Substance-Induced; Schizophrenia

Mesh:

Year:  2019        PMID: 31055966      PMCID: PMC6718312          DOI: 10.1176/appi.ajp.2019.18101217

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  17 in total

1.  Recurrence risks for schizophrenia in a Swedish national cohort.

Authors:  Paul Lichtenstein; Camilla Björk; Christina M Hultman; Edward Scolnick; Pamela Sklar; Patrick F Sullivan
Journal:  Psychol Med       Date:  2006-07-25       Impact factor: 7.723

2.  Genetic and familial environmental influences on the risk for drug abuse: a national Swedish adoption study.

Authors:  Kenneth S Kendler; Kristina Sundquist; Henrik Ohlsson; Karolina Palmér; Hermine Maes; Marilyn A Winkleby; Jan Sundquist
Journal:  Arch Gen Psychiatry       Date:  2012-07

3.  Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases.

Authors:  Mikkel Arendt; Raben Rosenberg; Leslie Foldager; Gurli Perto; Povl Munk-Jørgensen
Journal:  Br J Psychiatry       Date:  2005-12       Impact factor: 9.319

4.  Evaluation of diagnostic procedures in Swedish patients with schizophrenia and related psychoses.

Authors:  Birgit Ekholm; Andreas Ekholm; Rolf Adolfsson; Maria Vares; Urban Osby; Göran C Sedvall; Erik G Jönsson
Journal:  Nord J Psychiatry       Date:  2005       Impact factor: 2.202

5.  Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis.

Authors:  Chih-Ken Chen; Shih-Ku Lin; Pak C Sham; David Ball; El-Wui Loh; Robin M Murray
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2005-07-05       Impact factor: 3.568

Review 6.  Psychosis among substance users.

Authors:  Jagadisha Thirthalli; Vivek Benegal
Journal:  Curr Opin Psychiatry       Date:  2006-05       Impact factor: 4.741

7.  Long-term outcomes in methamphetamine psychosis patients after first hospitalisation.

Authors:  Phunnapa Kittirattanapaiboon; Suwat Mahatnirunkul; Hathaichonnee Booncharoen; Pornthip Thummawomg; Unchalee Dumrongchai; Worawan Chutha
Journal:  Drug Alcohol Rev       Date:  2010-07

8.  First-episode drug-induced psychosis: a medium term follow up study reveals a high-risk group.

Authors:  Kathleen Crebbin; Emma Mitford; Roger Paxton; Douglas Turkington
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-01-27       Impact factor: 4.328

9.  Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies.

Authors:  Patrick F Sullivan; Kenneth S Kendler; Michael C Neale
Journal:  Arch Gen Psychiatry       Date:  2003-12

10.  Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study.

Authors:  Paul Lichtenstein; Benjamin H Yip; Camilla Björk; Yudi Pawitan; Tyrone D Cannon; Patrick F Sullivan; Christina M Hultman
Journal:  Lancet       Date:  2009-01-17       Impact factor: 79.321

View more
  11 in total

1.  Cannabis legalization: Did we make a mistake? Update 2019

Authors:  Marco Leyton
Journal:  J Psychiatry Neurosci       Date:  2019-09-01       Impact factor: 6.186

2.  Diagnostic Difficulties and Treatment Challenges of a Young Patient With Severe Acute Psychosis and Complete Recovery.

Authors:  Jagoda Siembida; Saaduddin Mohammed; Mariam Chishty; Luba Leontieva
Journal:  Cureus       Date:  2022-04-01

3.  Effects of the Fyn kinase inhibitor saracatinib on ventral striatal activity during performance of an fMRI monetary incentive delay task in individuals family history positive or negative for alcohol use disorder. A pilot randomised trial.

Authors:  Krishna T Patel; Michael C Stevens; Amanda Dunlap; Alana Gallagher; Stephanie S O'Malley; Kelly DeMartini; Marc N Potenza; John H Krystal; Godfrey D Pearlson
Journal:  Neuropsychopharmacology       Date:  2021-09-02       Impact factor: 8.294

4.  Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis.

Authors:  Benjamin Murrie; Julia Lappin; Matthew Large; Grant Sara
Journal:  Schizophr Bull       Date:  2020-04-10       Impact factor: 9.306

Review 5.  Cannabis and Psychosis Through the Lens of DSM-5.

Authors:  Nathan T Pearson; James H Berry
Journal:  Int J Environ Res Public Health       Date:  2019-10-28       Impact factor: 3.390

6.  Composite immune marker scores associated with severe mental disorders and illness course.

Authors:  Monica Bettina Elkjaer Greenwood Ormerod; Thor Ueland; Maren Caroline Frogner Werner; Gabriela Hjell; Linn Rødevand; Linn Sofie Sæther; Synve Hoffart Lunding; Ingrid Torp Johansen; Torill Ueland; Trine Vik Lagerberg; Ingrid Melle; Srdjan Djurovic; Ole Andreas Andreassen; Nils Eiel Steen
Journal:  Brain Behav Immun Health       Date:  2022-07-02

7.  Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis.

Authors:  Tabea Schoeler; Jason Ferris; Adam R Winstock
Journal:  Transl Psychiatry       Date:  2022-09-06       Impact factor: 7.989

8.  Adverse effects of heavy cannabis use: even plants can harm the brain.

Authors:  Lucia Sideli; Giulia Trotta; Edoardo Spinazzola; Caterina La Cascia; Marta Di Forti
Journal:  Pain       Date:  2021-07-01       Impact factor: 6.961

9.  Mental health outcomes associated with of the use of amphetamines: A systematic review and meta-analysis.

Authors:  Rebecca McKetin; Janni Leung; Emily Stockings; Yan Huo; James Foulds; Julia M Lappin; Craig Cumming; Shalini Arunogiri; Jesse T Young; Grant Sara; Michael Farrell; Louisa Degenhardt
Journal:  EClinicalMedicine       Date:  2019-10-17

Review 10.  [Differential diagnostic distinction between substance-induced and primary psychoses: : Recommendations for general psychiatric and forensic practice].

Authors:  Dusan Hirjak; Andreas Meyer-Lindenberg; Geva A Brandt; Harald Dreßing
Journal:  Nervenarzt       Date:  2021-03-03       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.